Skip to Content
Søk Menu

EHA l European Hematology Association’s Annual Congress

EHA 2025

Azacitidine was generally well tolerated in patients ≥ 75 years of age in QUAZAR AML-001

  • / BestPractice Nordic

EHA-kongresside

  • / stine

EHA 2024

EHA-kongresside

  • / stine

Gå ikke glipp av de siste nyhetene fra ditt spesialområde

Registrer deg og få nye artikler, MEDtalks og digitale tidsskrifter direkte til din innboks

Få tilgang

Abstract EHA 2024

EHA-kongresside

  • / stine

Myelomatose

Iberdomide show promising efficacy in heavily pretreated patients with Relapsed/Refractory Multiple Myeloma

/ Hematologi / Sagar Lonial

EHA-ESMO Clinical Practice Guidelines for Multiple Myeloma

/ Hematologi / Fredrik Schjesvold

Potential to become the best treatment for multiple myeloma in history

/ Hematologi / Thierry Facon

New bispecific antibody with promising efficacy and safety profil for patients with relapsed/refractory Multiple Myeloma

/ Hematologi / Amrita Y. Krishnan

First-in-human study of teclistamab for relapsed/refractory Multiple Myeloma

/ Niels van de Donk
EHA21Myelomatose Play the Video

EHA 2022

Mer fra EHA

Ny MEDcast-serie

/ BestPractice Nordic
EHA21

Significant improvements in OS and RFS for older patients with AML

/ Farhad Ravandi
AMLEHA21 Play the Video

Highlights EHA 2021 (2:2)

/ Agoston Gyula Szabos
EHA21 Play the Video
Load more
Back to top